Provided by Tiger Trade Technology Pte. Ltd.

HORIZON KINETICS MEDICAL ETF

35.29
+0.59351.71%
Post-market: 35.380.0865+0.25%16:00 EDT
Volume:148
Turnover:5K
Market Cap:16.59M
PE:- -
High:35.29
Open:35.23
Low:35.23
Close:34.70
52wk High:37.90
52wk Low:30.79
Shares:469.95K
Float Shares:469.95K
Volume Ratio:0.41
T/O Rate:0.03%
Dividend:0.41
Dividend Rate:1.16%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

X4 Pharmaceuticals to Host Virtual Investor Day on Thursday, October 29, 2026, Featuring Key Opinion Leaders

GlobeNewswire
·
Yesterday

Eli Lilly announces new TOGETHER-PsO trial data

TIPRANKS
·
Yesterday

Lilly Says Phase 3b Together-PsO Data Show Broader Biomarker Shifts with Taltz Plus Zepbound vs Taltz Alone

Reuters
·
Yesterday

Eli Lilly price target lowered to $1,341 from $1,344 at BofA

TIPRANKS
·
Yesterday

Eli Lilly - Taltz and Zepbound Together Show Greater Reductions in Inflammatory Immune Activity

THOMSON REUTERS
·
Yesterday

Eli Lilly: Improvements were Maintained or Further Improved Through Week 52, with Safety Consistent with Known Profile of Each Respective Medicine

THOMSON REUTERS
·
Yesterday

New Phase 3B Data on Lilly's Taltz (Ixekizumab) and Zepbound (Tirzepatide) Advance Understanding of the Interconnected Immune and Metabolic Biology in Adults with Psoriasis and Obesity

THOMSON REUTERS
·
Yesterday

Top 3 Biotech Stocks To Watch In October 2026

Simply Wall St.
·
Yesterday

What Do Johnson & Johnson (JNJ) Trial Wins Mean For Its Drug Pipeline?

Simply Wall St.
·
Yesterday

Medtronic PLC Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Yesterday

Xortx Therapeutics outlines anticipated clinical trial application for XRx-026

TIPRANKS
·
Yesterday

Lilly’s Oral Orforglipron Trial Targets Early Obesity Risks, Raising the Stakes in Weight-Loss Pharma

TIPRANKS
·
Yesterday

AbbVie Targets Jawline and Neck Aesthetics With New Botox and Juvéderm Study

TIPRANKS
·
Yesterday

S&P 500 Top and Bottom Performing Stocks at About 12:00 P.m. EDT

Reuters
·
Yesterday

Argenx Stock Sinks as Scrapped Vyvgart Trial Erases $3.5 Billion Opportunity

Dow Jones
·
Oct 08

Dow's Nearly 150-Point Fall Led by Losses for Shares of Amgen, Johnson & Johnson

Dow Jones
·
Oct 08

AbbVie (ABBV) Lands Two FDA Breakthrough Tags For Temab A In Cancer

Simply Wall St.
·
Oct 08

1s Could Offer Unexpected Relief from Back and Knee Pain, but Doctors Urge Caution

Dow Jones
·
Oct 08

Zhongsheng Pharmaceutical's Class 1 Innovative Drug RAY1225 Injection Achieves Topline Analysis Results in Phase III Weight Loss Clinical Trial

Stock News
·
Oct 08

How to invest in healthcare stocks without picking the next Eli Lilly

Simply Wall St.
·
Oct 08